Response to letter entitled: Re: Efficacy and safety of regorafenib in patients with metastatic or locally-advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study.

Autor: Duffaud F; Aix Marseille University, APHM Hopital La Timone, Medical Oncology Unit, Marseille, France. Electronic address: Florence.DUFFAUD@ap-hm.fr., Schiffler C; Department of Statistics, Centre Léon Bérard, Lyon, France., Chabaud S; Department of Statistics, Centre Léon Bérard, Lyon, France., Blay JY; Medical Oncology Department, Centre Léon Bérard, Lyon, France.
Jazyk: angličtina
Zdroj: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Nov; Vol. 157, pp. 527-528. Date of Electronic Publication: 2021 Sep 08.
DOI: 10.1016/j.ejca.2021.08.009
Abstrakt: Competing Interests: Conflict of interest statement F. Duffaud received travel grants from Pharmamar, and Leo Pharma attended advisory boards for Bayer, Lilly. JY. Blay receives research support and honoraria from Eisei, Eli Lilly, MSD, BMS, GSK, Ignyta, Novartis, Pharmamar and Roche unrelated to this work. C. Schiffler and S. Chabaud have declared no conflicts of interest.
Databáze: MEDLINE
Externí odkaz: